학술논문
232 Lumacaftor/Ivacaftor is associated with a significant improvement in walk test and reduction in sweat chloride in a cohort of homozygous F508del CF patients with severe disease – a single centre experience
Document Type
Abstract
Author
Source
In Journal of Cystic Fibrosis June 2017 16 Supplement 1:S122-S122
Subject
Language
ISSN
1569-1993